MX2023001881A - Tratamiento con ribitol. - Google Patents
Tratamiento con ribitol.Info
- Publication number
- MX2023001881A MX2023001881A MX2023001881A MX2023001881A MX2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A
- Authority
- MX
- Mexico
- Prior art keywords
- ribitol
- treatment
- disorder
- disease
- treating
- Prior art date
Links
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 title abstract 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 title abstract 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076761P | 2020-09-10 | 2020-09-10 | |
| PCT/US2021/049677 WO2022056137A1 (en) | 2020-09-10 | 2021-09-09 | Ribitol treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001881A true MX2023001881A (es) | 2023-04-03 |
Family
ID=80629815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001881A MX2023001881A (es) | 2020-09-10 | 2021-09-09 | Tratamiento con ribitol. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364118A1 (enExample) |
| EP (1) | EP4210708A4 (enExample) |
| JP (1) | JP2023544249A (enExample) |
| KR (1) | KR20230069941A (enExample) |
| CN (1) | CN117355310A (enExample) |
| AU (1) | AU2021338706A1 (enExample) |
| CA (1) | CA3191582A1 (enExample) |
| IL (1) | IL301088A (enExample) |
| MX (1) | MX2023001881A (enExample) |
| WO (1) | WO2022056137A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| CN114269712A (zh) | 2019-05-28 | 2022-04-01 | 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 | 制备核糖醇的组合物和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245235B2 (en) * | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| WO2020041750A1 (en) * | 2018-08-24 | 2020-02-27 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Methods and compositions for treating disorders associated with muscle weakness |
-
2021
- 2021-09-09 MX MX2023001881A patent/MX2023001881A/es unknown
- 2021-09-09 CA CA3191582A patent/CA3191582A1/en active Pending
- 2021-09-09 EP EP21867600.5A patent/EP4210708A4/en active Pending
- 2021-09-09 KR KR1020237010497A patent/KR20230069941A/ko active Pending
- 2021-09-09 CN CN202180073484.0A patent/CN117355310A/zh active Pending
- 2021-09-09 US US18/044,747 patent/US20230364118A1/en active Pending
- 2021-09-09 AU AU2021338706A patent/AU2021338706A1/en active Pending
- 2021-09-09 WO PCT/US2021/049677 patent/WO2022056137A1/en not_active Ceased
- 2021-09-09 JP JP2023515723A patent/JP2023544249A/ja active Pending
- 2021-09-09 IL IL301088A patent/IL301088A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021338706A1 (en) | 2023-05-25 |
| WO2022056137A1 (en) | 2022-03-17 |
| US20230364118A1 (en) | 2023-11-16 |
| EP4210708A4 (en) | 2024-10-23 |
| WO2022056137A9 (en) | 2022-04-14 |
| JP2023544249A (ja) | 2023-10-23 |
| KR20230069941A (ko) | 2023-05-19 |
| CA3191582A1 (en) | 2022-03-17 |
| CN117355310A (zh) | 2024-01-05 |
| IL301088A (en) | 2023-05-01 |
| EP4210708A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
| BR112022007677A2 (pt) | L-asparaginase recombinante | |
| PH12021552763A1 (en) | Treatment and prevention of metabolic diseases | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| MX2023006146A (es) | Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| DE60036456D1 (de) | Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid | |
| MA56386B1 (fr) | Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale | |
| BR9808100A (pt) | Utilização de amandantina para tratamento de hepatite c. | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. | |
| MX2021013351A (es) | Terapias de combinacion. | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| AU2020327022A8 (en) | Method of treating cancer | |
| WO2021226442A3 (en) | Therapeutic uses of c3-binding agents | |
| BR112022010042A2 (pt) | Composições de hialuronidase e métodos de uso da mesma para tratar celulite | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| WO2019232203A3 (en) | Methods and compositions to alleviate vascular permeability | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante |